About: Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19()()()

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19()()() Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19()()()
Creator	Fox, Joshua Li, Yumeng Abrouk, Michael Cronin, Megan Frost, Phillip Galimberti, Fabrizio Herbst, Alexander Hoenig, Leonard Kirsner, Robert Mcbride, Jeffrey Rongioletti, Franco
Source	Elsevier; Medline; PMC; WHO
abstract	The emergence of the COVID-19 pandemic led to significant uncertainty among physicians and patients about the safety of immunosuppressive medications used for the management of dermatologic conditions. We review available data on commonly used immunosuppressants and their effect on viral infections beyond COVID-19. Notably, the effect of some immunosuppressants on viruses related to SARS-CoV2, including SARS and MERS, has been previously investigated. In the absence of data on the effect of immunosuppressants on COVID-19, these data could be used to make clinical decisions on initiation and continuation of immunosuppressive medications during this pandemic. In summary, we recommend considering the discontinuation of oral JAK inhibitors and prednisone, considering the delay of rituximab infusion, and the careful continuation of cyclosporine, mycophenolate, azathioprine, methotrexate, and biologics in patients currently benefitting from such treatments.
has issue date	2020-05-14(xsd:dateTime)
bibo:doi	10.1016/j.clindermatol.2020.05.003
bibo:pmid	32419721
has license	no-cc
sha1sum (hex)	cd4323398fcd68915291d7b9203268db7931cf3c
schema:url	https://doi.org/10.1016/j.clindermatol.2020.05.003
resource representing a document's title	Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19()()()
has PubMed Central identifier	PMC7224642
has PubMed identifier	32419721
schema:publication	Clin Dermatol
resource representing a document's body	covid:cd4323398fcd68915291d7b9203268db7931cf3c#body_text
is schema:about of	named entity 'BEYOND' named entity 'THESE' named entity 'INFUSION' named entity 'COULD BE' named entity 'AVAILABLE' named entity 'INITIATION' named entity 'COVID-19' named entity 'MERS' named entity 'CONSIDERING' named entity 'THEIR' named entity 'ORAL' named entity 'JOURNAL ' named entity 'TREATED WITH' named entity 'CONTINUATION' named entity 'Clinics in Dermatology' named entity 'COVID' named entity 'COVID-19 pandemic' named entity 'viruses' named entity 'JAK inhibitors' named entity 'biologics' named entity 'immunosuppressants' named entity 'COVID-19' named entity 'Evidenced-based' named entity 'Evidenced-based' named entity 'COVID-19' named entity 'immunosuppressive drugs' named entity 'antibody' named entity 'COVID' named entity 'feline' named entity 'epidemic' named entity 'infection rate' named entity 'prednisone' named entity 'COVID' named entity 'upper respiratory tract infection' named entity 'infection' named entity 'calcineurin' named entity 'SARS-CoV-2' named entity 'vaccination' named entity 'human immunodeficiency virus' named entity 'injectables' named entity 'TNF' named entity 'leukotrienes' named entity 'mice' named entity 'dermatologic' named entity 'injectable' named entity 'COVID' named entity 'phylogenetic' named entity 'injectables' named entity 'Covid' named entity 'flu' named entity 'herpes zoster' named entity 'B-cell' named entity 'immunosuppressants' named entity 'cyclophilin' named entity 'protein folding' named entity 'cytokines' named entity 'corticosteroids' named entity 'coronavirus disease 2019' named entity 'inflammatory cytokines' named entity 'SARS-CoV' named entity 'COVID-19' named entity 'SARS' named entity 'infection' named entity 'flu' named entity 'CsA' named entity 'herpes zoster' named entity 'biologics' named entity 'tumor necrosis factor' named entity 'IgG1' named entity 'epidemic' named entity 'Interferons'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software